CD8A and neoplasm: The ratio of OVA-reactive CD8+ T cells in the spleen increased significantly in VSIG4-KO and VSIG4 antibody-treated mice compared to that in the control group, and similar results were also found in tumor tissues (Fig. 4G-J).